Cingulate Inc banner

Cingulate Inc
NASDAQ:CING

Watchlist Manager
Cingulate Inc Logo
Cingulate Inc
NASDAQ:CING
Watchlist
Price: 5.37 USD 4.27% Market Closed
Market Cap: $62.4m

Multiples-Based Value

CING doesn't have a meaningful market cap.

The Multiples-Based Value for Cingulate Inc (CING) under the Base Case is hidden USD. Compared with the current market price of 5.37 USD, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CING Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

CING Competitors Multiples
Cingulate Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cingulate Inc
NASDAQ:CING
62.4m USD 0 -2.8 -3 -3
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 12.6 36 26.1 27.6
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 5.7 26 16.7 21.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.2 20.1 11.9 13.4
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 27.4 14.9 20.8
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7 13.4 17.4
US
Merck & Co Inc
NYSE:MRK
277.6B USD 4.2 31.1 13.7 18.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.1 8.8 10.4
US
Pfizer Inc
NYSE:PFE
149.7B USD 2.4 19.3 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 407.7 4 516.9 16.3 16.5
P/E Multiple
Earnings Growth PEG
US
Cingulate Inc
NASDAQ:CING
Average P/E: 523.3
Negative Multiple: -2.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cingulate Inc
NASDAQ:CING
Average EV/EBITDA: 51.6
Negative Multiple: -3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
26.1
21%
1.2
US
Johnson & Johnson
NYSE:JNJ
16.7
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.9
6%
2
UK
AstraZeneca PLC
LSE:AZN
14.9
12%
1.2
CH
Novartis AG
SIX:NOVN
13.4
5%
2.7
US
Merck & Co Inc
NYSE:MRK
13.7
6%
2.3
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.8
2%
4.4
US
Pfizer Inc
NYSE:PFE
7.5
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
16.3
33%
0.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cingulate Inc
NASDAQ:CING
Average EV/EBIT: 112.6
Negative Multiple: -3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.6
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.3
13%
1.6
CH
Roche Holding AG
SIX:ROG
13.4
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
20.8
21%
1
CH
Novartis AG
SIX:NOVN
17.4
9%
1.9
US
Merck & Co Inc
NYSE:MRK
18.5
10%
1.9
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
2%
5.2
US
Pfizer Inc
NYSE:PFE
10
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
16.5
28%
0.6
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett